The Swiss-based biotech firm Penny Relief Therapeutics (OTC: RLFTF) had not really good share trading this week as compared to last Friday’s sharp rise to $0.4515. Only 4.11% growth happened on this Friday after Thanksgiving day which ate up whole trading hours. Maybe 3% growth could happen to the stock on Thursday if no celebration came up.
November became a month of digging for RLFTF as the shares fell sharply from $0.53 to $0.2520 on the fourth day of the month. But investors are optimistic about RLF-100 development and still gratefully waiting for further clinical updates. In Europe, several biotech firms are competing to develop the most effective vaccine for COVID-19. Currently, American peers are leading the rally as the government funds them thoroughly.
In the last updates from NeuroRx and Relief; RLF-100 (aviptadil) could deliver 72% survived patients out of 90 within 28 days. The phase 2b/3 is still going on to check the efficacy of aviptadil for treating patients with critical and severe conditions. So far Pfizer and Moderna do not have such strong vaccines to fight those patients as their candidates are the most effective to early stages of the coronavirus.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.